Gainers

• Viridian Therapeutics (NASDAQ:VRDN) shares rose 30.7% to $18.37 during Tuesday's regular session. The company's market cap stands at $1.4 billion. As per the press release, Q1 earnings came out today.
• Biodesix (NASDAQ:BDSX) shares rose 29.37% to $14.58. The company's market cap stands at $90.1 million. As per the press release, Q1 earnings came out yesterday.
• Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 27.24% to $3.97. The company's market cap stands at $10.1 million.
• Fortrea Holdings (NASDAQ:FTRE) shares increased by 25.14% to $15.33. The company's market cap stands at $1.1 billion. The company's, Q1 earnings came out today.
• Cellectar Biosciences (NASDAQ:CLRB) shares rose 24.13% to $3.51. The company's market cap stands at $11.9 million.
• Lixte Biotechnology Hldgs (NASDAQ:LIXT) shares moved upwards by 23.1% to $4.05. The market value of their outstanding shares is at $38.2 million.

Losers

• Embecta (NASDAQ:EMBC) shares fell 55.2% to $4.14 during Tuesday's regular session. The market value of their outstanding shares is at $547.7 million. As per the press release, Q2 earnings came out today.
• GeneDx Holdings (NASDAQ:WGS) stock declined by 49.81% to $34.09. The company's market cap stands at $1.9 billion. As per the press release, Q1 earnings came out yesterday.
• Picard Medical (AMEX:PMI) shares decreased by 41.2% to $0.21. The company's market cap stands at $26.5 million.
• Akanda (NASDAQ:AKAN) stock decreased by 36.31% to $26.16. The market value of their outstanding shares is at $21.9 million.
• Onconetix (NASDAQ:ONCO) stock decreased by 20.22% to $0.52. The market value of their outstanding shares is at $7.4 million.
• Ocugen (NASDAQ:OCGN) shares decreased by 19.19% to $1.5. The company's market cap stands at $626.2 million. As per the press release, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.